Synagis

What is this medication? Synagis, which is known by the generic name palivizumab, is a prescription medication used to help prevent serious lung infections caused by the respiratory syncytial virus, commonly referred to as RSV. It is classified as a monoclonal antibody rather than a vaccine, meaning it provides the body with specific proteins that help block the virus from infecting cells. This treatment is not designed to cure or treat a child who is already sick with RSV, but rather to serve as a preventative measure for those most likely to become severely ill.

The medication is primarily prescribed for infants and young children who are considered at high risk for complications. This includes babies born prematurely and those with certain medical conditions, such as chronic lung disease or specific types of congenital heart disease. Because RSV is seasonal, the medication is typically administered as an injection once a month throughout the months when the virus is most active in the community.